Global Perspective on BRCA Mutations, PARPi, and Biomarker-Driven Strategies in Pancreatic Cancer

Get up to date with international insights on assessing and targeting BRCA1/2 and other DNA damage repair gene alterations in pancreatic cancer with downloadable slides and on-demand Webcast from a live Webinar plus an expert commentary.
person default
Dirk Arnold, MD, PhD

ClinicalThought

Now that olaparib is approved in the EU, how will your treatment of patients with pancreatic cancer change?

person default Dirk Arnold, MD, PhD Released: October 30, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue